ReviewSeminars in oncology2013
Cognitive effects of cancer and its treatments at the intersection of aging: what do we know; what do we need to know?
Review in Seminars in oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed, 7 syntheses or guidelines pooled it, 135 citations in OpenAlex.
- Could Subjective Cognitive Complaints Give the Facts of Objective Cognitive Impairments in Non-Central Nervous System Cancer? A Systematic Review.Brain and behavior · 2026Pooled it
- Chemotherapy-induced cognitive impairment in breast cancer survivors: A systematic review of studies from 2000 to 2021.Cancer reports (Hoboken, N.J.) · 2024Pooled it
- Young Adult Cancer Survivorship: Recommendations for Patient Follow-up, Exercise Therapy, and Research.JNCI cancer spectrum · 2021Guideline
- Physical Therapies for Psychosomatic Symptoms and Quality of Life Induced by Aromatase Inhibitors in Breast Cancer Patients: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Systematic review of cognitive sequelae of non-central nervous system cancer and cancer therapy.Journal of cancer survivorship : research and practice · 2020Pooled it
- Understanding the Profile of Cancer-Related Cognitive Impairments: A Critique of Meta-Analyses.Journal of the National Cancer Institute · 2019Pooled it
- Structural brain alterations following adult non-CNS cancers: a systematic review of the neuroimaging literature.Acta oncologica (Stockholm, Sweden) · 2019Pooled it
- Trial
- DNA Methylation of BDNF and RASA2 Genes Is Associated With Cognitive Function in Postmenopausal Women With Breast Cancer.Oncology nursing forum · 2024Trial
- Trial
- Subjective cognition and mood in persistent chemotherapy-related cognitive impairment.Journal of cancer survivorship : research and practice · 2022Trial
- Nicotinic treatment of post-chemotherapy subjective cognitive impairment: a pilot study.Journal of cancer survivorship : research and practice · 2019Trial
- Acute aerobic exercise effects on cognitive function in breast cancer survivors: a randomized crossover trial.BMC cancer · 2019Trial
- Trial
- Moderate Physical Activity Mediates the Association between White Matter Lesion Volume and Memory Recall in Breast Cancer Survivors.PloS one · 2016Trial
- Unveiling the cognitive fog in lung cancer patients: non-invasive exploration of blood-brain barrier disruption and brain structural changes.Annals of medicine · 2026Article
- Cognitive Impairment in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Cross-Sectional Study.Journal of clinical medicine · 2026Article
- Synergistic effects of group-based exercise to reduce loneliness and social isolation and to prevent cognitive decline among older adults with cancer.Frontiers in aging · 2026Article
- Advances in neuroimaging in cancer-related cognitive impairment.Frontiers in human neuroscience · 2026Review
- Accelerated Brain Aging, Atherogenicity, and Neurocognition in Adult Survivors of Childhood Cancer.JAMA network open · 2025Article
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 7 institutions in 1 country.
Funding
Abstract
There is a fairly consistent, albeit non-universal body of research documenting cognitive declines after cancer and its treatments. While few of these studies have included subjects aged 65 years and older, it is logical to expect that older patients are at risk of cognitive decline. Here, we use breast cancer as an exemplar disease for inquiry into the intersection of aging and cognitive effects of cancer and its therapies. There are a striking number of common underlying potential biological risks and pathways for the development of cancer, cancer-related cognitive declines, and aging processes, including the development of a frail phenotype. Candidate shared pathways include changes in hormonal milieu, inflammation, oxidative stress, DNA damage and compromised DNA repair, genetic susceptibility, decreased brain blood flow or disruption of the blood-brain barrier, direct neurotoxicity, decreased telomere length, and cell senescence. There also are similar structure and functional changes seen in brain imaging studies of cancer patients and those seen with "normal" aging and Alzheimer's disease. Disentangling the role of these overlapping processes is difficult since they require aged animal models and large samples of older human subjects. From what we do know, frailty and its low cognitive reserve seem to be a clinically useful marker of risk for cognitive decline after cancer and its treatments. This and other results from this review suggest the value of geriatric assessments to identify older patients at the highest risk of cognitive decline. Further research is needed to understand the interactions between aging, genetic predisposition, lifestyle factors, and frailty phenotypes to best identify the subgroups of older patients at greatest risk for decline and to develop behavioral and pharmacological interventions targeting this group. We recommend that basic science and population trials be developed specifically for older hosts with intermediate endpoints of relevance to this group, including cognitive function and trajectories of frailty. Clinicians and their older patients can advance the field by active encouragement of and participation in research designed to improve the care and outcomes of the growing population of older cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.